Scarica l'app Stockscreener
5.365
4.99%
0.255
Dopo l'orario di chiusura:
5.44
0.075
+1.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.11
Aprire:
$5.01
Volume 24 ore:
71,387
Relative Volume:
0.53
Capitalizzazione di mercato:
$46.20M
Reddito:
-
Utile/perdita netta:
$-34.77M
Rapporto P/E:
-1.621
EPS:
-3.3097
Flusso di cassa netto:
$-29.79M
1 W Prestazione:
+13.91%
1M Prestazione:
+19.22%
6M Prestazione:
-61.12%
1 anno Prestazione:
-47.98%
Intervallo 1D:
$5.00
$5.56
Intervallo di 1 settimana:
$4.59
$5.56
Portata 52W:
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Nome
Atossa Therapeutics Inc
Settore
Industria
Telefono
206.588.0256
Indirizzo
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
5.365 | 46.20M | 0 | -34.77M | -29.79M | -3.3097 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-01-26 | Iniziato | Maxim Group | Buy |
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Atossa Therapeutics Seeks Shareholder Approval for Further Stock Consolidation - AD HOC NEWS
Atossa (NASDAQ: ATOS) CEO Steven Quay granted 65,000 RSUs after reverse split - Stock Titan
Atossa Therapeutics announces issuance of U.S. patent - MSN
Atossa Therapeutics (ATOS) CFO receives 63,000 RSUs over 3 years - Stock Titan
[ARS] ATOSSA THERAPEUTICS, INC. SEC Filing - Stock Titan
[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement - Stock Titan
NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation - Traders Union
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Entry Recap: Is Atossa Therapeutics Inc a speculative investment2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Risk Off: Is Atossa Therapeutics Inc stock heavily shorted2026 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn
H.C. Wainwright raises Atossa Genetics price target to $25 from $7 - Investing.com
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
ATOS Receives Significant Price Target Increase from HC Wainwrig - GuruFocus
Atossa Therapeutics (ATOS) Sees Increased Price Target Following Stock Split - GuruFocus
Aug Weekly: Is Atossa Therapeutics Incs growth already priced in2026 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Atossa Therapeutics Reports 2025 Financial Results and Advances (Z)-Endoxifen in Rare Diseases and Oncology - Minichart
ATOSSA THERAPEUTICS INC reports Q4 and full year 2025 results and unveils corporate update - Traders Union
Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss - GuruFocus
Atossa Therapeutics 2025 Annual Report: (Z)-Endoxifen Clinical Development, Intellectual Property, and Regulatory Strategy - Minichart
Atossa Genetics Investors to Decide on Key Corporate Proposals - AD HOC NEWS
ATOS Advances in Drug Development with Strategic Focus - GuruFocus
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - Fidelity
Atossa Therapeutics 2025 10-K: $0.0M Revenue; Net loss $34.8M - TradingView
Atossa Therapeutics (NASDAQ: ATOS) boosts cash options but warns on going concern - Stock Titan
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
R&D spending jumps as Atossa (NASDAQ: ATOS) advances (Z)-endoxifen programs - Stock Titan
Atossa Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Atossa Therapeutics (NASDAQ: ATOS) asks shareholders to OK 2:1–20:1 reverse split - Stock Titan
Atossa Therapeutics Inc expected to post a loss of $1.14 a shareEarnings Preview - TradingView
Atossa Therapeutics Appoints Two New Medical Directors in Breast Oncology and Rare Diseases - Contract Pharma
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - The Globe and Mail
Atossa Therapeutics Strengthens Clinical Leadership Team with th - GuruFocus
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives - PR Newswire
Should I set a stop loss on Atossa Therapeutics Inc2026 Decliners & Growth Focused Stock Pick Reports - baoquankhu1.vn
Atossa Therapeutics announces launch of early-stage DMD program for rare disease awareness - Traders Union
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - Sahm
Atossa presents preclinical data on endoxifen for muscular dystrophy - Investing.com South Africa
Atossa presents preclinical data on endoxifen for muscular dystrophy By Investing.com - Investing.com Australia
Atossa Therapeutics, Inc. Presents Clinical Trial Update On Z-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - marketscreener.com
Atossa Therapeutics shares clinical trial update for Z-endoxifen at MDA conference - Traders Union
Big Money Moves: Is Atossa Therapeutics Inc a potential multi bagger2026 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Muscle biomarker improvement reported in dystrophic mice, Atossa Therapeutics asserts - Traders Union
Is Atossa Therapeutics Inc likely to announce a buybackJuly 2025 Momentum & Reliable Entry Point Alerts - baoquankhu1.vn
Hedge Fund Moves: Is Atossa Therapeutics Inc stock undervalued right nowJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
CEO Moves: Is Atossa Therapeutics Inc a speculative investmentQuarterly Market Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Cash from operating activities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Cash from financing activities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Free cash flow of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Aug Fed Impact: Is Atossa Therapeutics Inc stock undervalued right nowQuarterly Profit Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Total liabilities & shareholders' equities of Atossa Therapeutics, Inc. – MUN:YAG - TradingView
Atossa Therapeutics advances Z-endoxifen platform in oncology and DMD targeting molecular precision - Traders Union
Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):